The Kerala High Court has ruled that the central government can intervene on high-priced patented medicines under the Patents Act, specifically citing cancer drugs abemaciclib and ribociclib. The court directed authorities to assess nationwide drug affordability, signaling potential regulatory scrutiny for multinational pharmaceutical firms. Investors should monitor how the government defines affordability and its potential impact on premium oncology drug pricing.
The Kerala High Court has issued a significant legal observation regarding the pricing of patented, life-saving medicines in India. The court confirmed that the central government holds the authority under Section 100 of the Patents Act to intervene when the cost of critical medication limits public access. While the court did not mandate an immediate change in drug prices, it directed government authorities to initiate a nationwide assessment of drug affordability, with specific attention toward breast cancer treatments like abemaciclib and ribociclib.
Section 100 of the Patents Act allows the government to authorize the manufacturing of patented drugs for state use without the consent of the patent holder, provided the medication is distributed for non-commercial purposes. In this instance, the court rejected the argument that such powers are restricted only to national security or specific institutional needs, emphasizing that protecting public health is a fundamental government responsibility. This interpretation expands the scope for state intervention in the pharmaceutical sector.
The case centers on high-value oncology drugs currently marketed by multinational pharmaceutical companies. Eli Lilly holds the patent for abemaciclib, while Novartis holds the patent for ribociclib. Both drugs are used to treat HR-positive, HER2-negative breast cancer. Critics of current pricing levels have argued that high costs for these treatments create barriers for patients, necessitating government action to ensure wider access. Multinational pharmaceutical companies have traditionally relied on patent protections to sustain high margins in the Indian market, which this ruling could potentially challenge.
For investors, the key implication is the increased risk of regulatory intervention in the pricing of high-value, patented products. Although the court has stopped short of ordering immediate price caps, the move signals that the judiciary is open to the government using existing legal tools to address high drug costs. The next important step for investors to monitor is the Ministry of Health's nationwide affordability assessment. The methodology used to define when a drug is 'unaffordable' and the government's subsequent approach to these patent rights will likely determine the long-term impact on the pricing models of multinational drug manufacturers in India. If the government establishes clear thresholds for intervention, it could lead to increased pressure on the margins of premium oncology products and a shift in how patent-protected drugs are introduced and priced in the country.